Ämnen: Hälso-, sjukvård

Danmark: Først blandt de nordiske lande til at tilbyde Andembry® – CSL Behrings nye forebyggende behandling til hereditært angioødem (HAE)

5 November 2025 09:02

Andembry® repræsenterer et væsentligt fremskridt indenfor behandling af HAE; med Danmark som det første land i Norden, hvor Andembry® er tilgængeligt og tilbydes som en ny mulighed til forebyggende behandling. Andembry® er det første og eneste faktor XIIa-hæmmende monoklonale antistof (anti-FXIIa mAb), med subkutan dosering én gang om måneden fra behandlingsstart.

CSL Behring’s Gene Therapy HEMGENIX (etranacogene dezaparvovec): Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Haemophilia B

11 Februari 2025 08:34

94% of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment. Mean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX® in the treatment of haemophilia B.

CSL Behring Appoints Helena Bragd as New General Manager for the Nordic Region

28 Januari 2025 08:31

Helena Bragd is the new General Manager of CSL Behring Nordic Region – Sweden, Denmark, Norway, Finland, and Iceland. CSL Behring is a global biotherapeutics leader driven by our promise to save lives.

First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark

21 Januari 2025 08:26

CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is the first one-time gene therapy to be approved in Europe for the treatment of adults with severe and moderately severe haemophilia B.

CSL Behring Signs Milestone Commercial Agreement with Amgros to Fund Haemophilia B Gene Therapy HEMGENIX in Denmark

29 Oktober 2024 09:34

CSL Behring today announced that an outcome-based agreement has been reached with Amgros, the Danish procurement authority, for the national reimbursement of HEMGENIX® in Denmark. Denmark is the first country in the Nordic region to reimburse HEMGENIX® under such a performance-based model, in which the regions only incur costs if the gene therapy proves effective over an agreed long-term period.

CSL Behring uppmärksammar Världshemofilidagen och alla som lever med blödarsjuka

15 April 2024 08:57

Den 17 april är det Världshemofilidagen som i år har fokus på rättvis tillgång till behandling för alla med blödarsjuka. CSL Behring är ett globalt bioteknikföretag som drivs av löftet att rädda och förbättra människors liv. Forskningen inom hemofili har gjort stora framsteg under de senaste åren som har lett till nya behandlingsformer.

CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance

15 December 2023 13:45

These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has been serving for over 40 years, in the US and European Union.